Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIDIL vs VERTAVIS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (a direct vasodilator). Isosorbide dinitrate relaxes vascular smooth muscle via NO-mediated c GMP production; hydralazine reduces peripheral resistance and may inhibit DNA synthesis in endothelial cells. Synergy enhances vasodilation and improves cardiac output.
Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.
Heart failure: treatment to improve survival, prolong time to hospitalization, and improve quality of life in self-identified black patients with heart failure (NYHA class III-IV) receiving standard therapy (diuretics, ACE inhibitors/ARBs, beta-blockers). Off-label: none significant.
Treatment of mild to moderate Alzheimer's disease,Off-label: treatment of other dementias, myasthenia gravis
Isosorbide dinitrate 20 mg plus hydralazine 37.5 mg orally three times daily; titrate to target dose of isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily as tolerated.
5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); isosorbide dinitrate: 1 hour (parent), 4-5 hours (isosorbide-5-mononitrate, active metabolite). Clinical context: Requires twice-daily dosing for sustained effect.
Terminal elimination half-life is 39–58 hours (mean 49 hours), supporting once-daily dosing. Steady state is achieved after 7–10 days.
Isosorbide dinitrate: extensively metabolized by denitration and conjugation in the liver; hydralazine: primarily metabolized by N-acetylation (N-acetyltransferase 2, NAT2) and subsequent glucuronidation.
Primarily hydrolyzed by plasma esterases; minor hepatic metabolism via CYP450 enzymes.
Hydralazine: 80% renal (as active drug and metabolites, predominantly N-acetylhydralazine and hydralazine pyruvic acid hydrazone); isosorbide dinitrate: renal (metabolites, primarily isosorbide mononitrates and isosorbide) and fecal (minor).
Approximately 70% of the dose is excreted renally as unchanged drug and 30% via biliary/fecal routes as metabolites.
Hydralazine: 87-90% (plasma proteins); isosorbide dinitrate: 30-40% (albumin).
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Hydralazine: 1.6 L/kg; isosorbide dinitrate: 2-4 L/kg. Clinical meaning: Extensive tissue distribution for both components.
Volume of distribution is 0.4–0.6 L/kg (approx 30–50 L in adults), indicating distribution primarily into extracellular fluid.
Hydralazine: 30-50% (oral, first-pass effect); isosorbide dinitrate: 20-30% (oral, extensive first-pass metabolism).
Oral bioavailability is approximately 50% (range 30–70%) with food reducing rate but not extent of absorption.
No specific dose adjustment recommended; however, hydralazine is cleared renally and may accumulate in severe renal impairment (Cr Cl <30 m L/min); consider monitoring for adverse effects.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use is not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment but caution advised due to potential increased exposure.
Not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No data available.
Safety and efficacy not established in pediatric patients; no standard dosing recommendations available.
Safety and efficacy not established; no recommended dose.
Initiate at lower end of dosing range; titrate slowly due to increased risk of hypotension and dizziness; monitor renal function as hydralazine clearance may decrease.
No specific dose adjustment; use with caution due to potential increased sensitivity and comorbidities.
None.
No FDA black box warning.
Hypotension (monitor blood pressure), agranulocytosis (rare; hydralazine may cause neutropenia; monitor CBC), drug-induced lupus-like syndrome (hydralazine; discontinue if symptoms develop), hepatotoxicity (hydralazine; monitor liver enzymes), risk of syncope when initiating or increasing dose, volume depletion (correct before use).
Cardiovascular effects (bradycardia, syncope),Gastrointestinal effects (nausea, vomiting, diarrhea),Seizures,Weight loss
Hypersensitivity to hydralazine or isosorbide dinitrate, severe hypotension (<100 mm Hg systolic), acute myocardial infarction (safety not established), cardiogenic shock, cardiomyopathy with restrictive/obstructive physiology, use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypersensitivity to Vertavis or any component,History of severe cholinergic adverse effects
No specific food interactions. Avoid excessive alcohol intake as it may exacerbate hypotension.
Avoid grapefruit and grapefruit juice as they may increase ergotamine levels and risk of toxicity. Limit caffeine intake as it can exacerbate headache and interact with ergotamine. Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) if migraines are triggered by tyramine.
FDA Pregnancy Category C. First trimester: Animal studies show fetal harm; no adequate human studies. Second and third trimesters: Hydralazine crosses placenta; may cause fetal hypotension, thrombocytopenia. Isosorbide dinitrate: Limited data; associated with methemoglobinemia in neonates. Use only if benefit outweighs risk.
Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures below human clinical exposure at 400 mg/day. First trimester: high risk of major congenital malformations; second and third trimesters: risk of fetal growth restriction and fetal death.
Hydralazine is excreted in breast milk (M/P ratio ~1.2); low levels unlikely to harm infant. Isosorbide dinitrate: No data on excretion. Monitor infant for hypotension. American Academy of Pediatrics considers hydralazine compatible with breastfeeding.
Contraindicated during breastfeeding. No data on presence in human milk; however, animal studies show drug and metabolites are excreted in milk. M/P ratio not known. Due to potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 3 weeks after last dose.
Pregnancy may increase volume of distribution and clearance of hydralazine; dose adjustments may be needed to maintain efficacy. Isosorbide dinitrate: no specific recommendations; start at lowest effective dose and titrate based on blood pressure response. Monitor for orthostatic hypotension.
No dose adjustments recommended during pregnancy as the drug is contraindicated. If unintentionally exposed, discontinue immediately. Physiologic changes in pregnancy may alter drug pharmacokinetics (e.g., increased volume of distribution, increased hepatic clearance), but no specific dose adjustment has been studied in pregnant women.
Bidil is a fixed-dose combination of isosorbide dinitrate (20 mg) and hydralazine (37.5 mg), indicated as an adjunct to standard therapy for heart failure in self-identified African American patients (NYHA class III-IV, left ventricular ejection fraction <45%). Dizziness and headache are common due to vasodilation; titrate slowly. Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Monitor for fluid retention and worsening heart failure. Consider dose reduction in hepatic impairment.
Vertavis (a combination of phenobarbital, ergotamine, and belladonna alkaloids) is used for migraine and tension-type headaches. Monitor for signs of ergotism (numbness, cold extremities, muscle pain) due to ergotamine; avoid prolonged use. Phenobarbital is a controlled substance (C-IV) with abuse potential; monitor for sedation and dependence. Belladonna alkaloids cause anticholinergic effects (dry mouth, blurred vision, urinary retention). Taper dose to avoid withdrawal; avoid in patients with peripheral vascular disease, coronary artery disease, or glaucoma.
Take this medication exactly as prescribed, usually three times daily with or without food.,Do not take with erectile dysfunction drugs (e.g., Viagra, Cialis, Levitra) as this can cause a dangerous drop in blood pressure.,Common side effects include dizziness and headache, which may improve over time; report severe or persistent symptoms to your doctor.,Avoid sudden position changes to prevent falls.,Do not stop taking this medication abruptly without consulting your healthcare provider.,Inform all healthcare providers you are taking Bidil.,Store at room temperature, away from moisture and heat.
Take Vertavis at the first sign of headache; do not exceed recommended dose.,Do not use more than 10 days per month to avoid medication-overuse headache and ergotamine toxicity.,Report symptoms of ergotism such as cold fingers or toes, numbness, tingling, or muscle pain immediately.,This medication may cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Avoid alcohol; it can increase sedation and ergotamine side effects.,Do not suddenly stop taking this medication; withdrawal may cause rebound headaches or seizures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIDIL vs VERTAVIS, answered by our medical review team.
BIDIL is a Vasodilator Combination that works by Combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (a direct vasodilator). Isosorbide dinitrate relaxes vascular smooth muscle via NO-mediated c GMP production; hydralazine reduces peripheral resistance and may inhibit DNA synthesis in endothelial cells. Synergy enhances vasodilation and improves cardiac output.. VERTAVIS is a Prostacyclin Vasodilator that works by Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIDIL and VERTAVIS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIDIL is: Isosorbide dinitrate 20 mg plus hydralazine 37.5 mg orally three times daily; titrate to target dose of isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily as tolerated.. The standard adult dose of VERTAVIS is: 5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIDIL and VERTAVIS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIDIL is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal harm; no adequate human studies. Second and third trimesters: Hydralazine crosses placenta; may cause fetal hyp. VERTAVIS is classified as Category C. Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures bel. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.